All In Biotech

Drug Trial Radar · NCT06470373

A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular Degeneration

A Phase 3 Clinical Trial to Compare Efficacy, Safety, Tolerability and Immunogenicity of RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular Degeneration

Last checked: Nov 20, 2026Latest source record: Apr 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 434 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

434

Planned (sponsor's estimate)

Start

Jul 2025

Primary completion

Sep 2026

Study completion Sep 2026

Sponsor

Lead sponsor
Rophibio, Inc.Industry
Sponsor type
Industry
First posted
Jun 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical study is designed to demonstrate the equivalence of the two Investigational Products by comparing the efficacy, safety, tolerability and immunogenicity of RBS-001 and Eylea® in subjects with Neovascular age-related macular degeneration.

Conditions

  • Neovascular Age-related Macular Degeneration (nAMD)

Interventions

  • RBS-001 Solution for intravitreal injectionDrug

    Administer 2 mg/eye (50 uL/eye) per dose of the IP via IVT to the subjects' study eye

  • Eylea® Solution for intravitreal injectionDrug

    Administer 2 mg/eye (50 uL/eye) per dose of the IP via IVT to the subjects' study eye

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Best-Corrected Visual Acuity (BCVA) measured by Early treatment Diabetic Retinopathy Study (ETDRS) letter score at 8 weeks after the IP treatmentTime frame: The change from baseline (Day 1) to 8 weeks after the IP treatment

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Associated Retina Consultants - Phoenix

    Phoenix, Arizona

  • Associated Retina Consultants - Gilbert

    Phoenix, Arizona

  • Retina Partners of Northwest Arkansas, PLLC

    Springdale, Arkansas

  • Erie Retina Research

    Erie, Pennsylvania

  • Charles Retina Institute

    Germantown, Tennessee

  • Retina Research Institute of Texas

    Abilene, Texas

  • Strategic Clinical Research Group, LLC

    Willow Park, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.